Retirement Systems of Alabama Sells 662,087 Shares of Pfizer Inc. (NYSE:PFE)

Retirement Systems of Alabama lessened its position in Pfizer Inc. (NYSE:PFE) by 34.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,244,417 shares of the biopharmaceutical company’s stock after selling 662,087 shares during the quarter. Retirement Systems of Alabama’s holdings in Pfizer were worth $35,827,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. MCF Advisors LLC increased its holdings in shares of Pfizer by 3.7% during the 3rd quarter. MCF Advisors LLC now owns 27,590 shares of the biopharmaceutical company’s stock worth $915,000 after purchasing an additional 975 shares during the period. U.S. Capital Wealth Advisors LLC increased its holdings in shares of Pfizer by 18.5% during the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 503,170 shares of the biopharmaceutical company’s stock worth $16,690,000 after purchasing an additional 78,421 shares during the period. Trust Co. of Toledo NA OH increased its holdings in shares of Pfizer by 2.1% during the 3rd quarter. Trust Co. of Toledo NA OH now owns 122,829 shares of the biopharmaceutical company’s stock worth $4,074,000 after purchasing an additional 2,567 shares during the period. JGP Wealth Management LLC increased its holdings in shares of Pfizer by 3.4% during the 3rd quarter. JGP Wealth Management LLC now owns 60,487 shares of the biopharmaceutical company’s stock worth $2,006,000 after purchasing an additional 2,000 shares during the period. Finally, Blossom Wealth Management increased its holdings in shares of Pfizer by 11.5% during the 3rd quarter. Blossom Wealth Management now owns 10,943 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 1,130 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $25.51 on Monday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a market cap of $144.45 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. The company’s 50-day moving average is $26.96 and its two-hundred day moving average is $28.36.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the company posted $1.14 EPS. The company’s revenue was down 41.3% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.59%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.